Mesenchymal stem cell therapy - Hanyang University/SCM Lifescience
Alternative Names: Spheroid cell therapyLatest Information Update: 28 May 2024
At a glance
- Originator SCM Lifescience
- Developer Hanyang University; SCM Lifescience
- Class Foot disorder therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic foot ulcer; Wounds
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Wounds in South Korea (Parenteral)
- 28 May 2024 No recent reports of development identified for research development in Diabetic-foot-ulcer in South Korea (Parenteral)
- 07 Apr 2020 Early research in Diabetic foot ulcer in South Korea (Parenteral), prior to April 2020 (SCM Lifescience pipeline, April 2020)